Why Biohaven Ltd.’s (BHVN) Stock Is Down 5.55%
As of Tuesday, October 06, Biohaven Ltd.’s BHVN share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Commentary & Analysis
Why Biohaven Ltd.’s (BHVN) Stock Is Down 5.63%
As of Thursday, September 24, Biohaven Ltd.’s BHVN share price has dipped by 5.63%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Biohaven Ltd.’s (BHVN) Stock Is Down 5.05%
As of Wednesday, September 23, Biohaven Ltd.’s BHVN share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Michael Rose
Why Biohaven Ltd.’s (BHVN) Stock Is Up 5.21%
As of Monday, September 21, Biohaven Ltd.’s BHVN share price has surged by 5.21%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Biohaven Ltd.’s (BHVN) Stock Is Up 7.65%
As of Thursday, September 17, Biohaven Ltd.’s BHVN share price has surged by 7.65%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | BHVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,783.8 | $237.5 | 53% |
|
| Shares Out (Mil) | 150.6 | 53.9 | 71% |
|
| Institutional Ownership | 88.3% | 93.1% | 56% |
|
| Float (Mil) | 116.6 | 41.4 | 64% |
|
| Beta | 3.17 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 1,877 | 628 | 80% |
|
| Price Change (52-week) |
(31.5%) | 49.0% | 29% |
|
| Growth | BHVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.4% | na |
|
| Net Income (5yr) | (44.2%) | (10.2%) | 8% |
|
| EPS (5yr) | (17.9%) | 15.7% | 15 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (8.3%) | (15.7%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | $0.165 | ($1.649) | ($1.872) | |
| Month Ago EPS | $0.165 | ($1.649) | ($1.872) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.573) | ($2.395) | ($1.950) | |
| Year/Year Chg | (118.1%) | (76.0%) | (75.9%) | |
| Financials | BHVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($587) | ($44) | 2% |
|
| EPS (TTM) | ($4.476) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($511) | ($33) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $72 | $2 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $292 | $4 | 53% |
|
| Enterprise Value (Q1) (Mil) | $2,177 | $174 | 50% |
|
| Valuation | BHVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 147.63 | 2.27 | 100% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BHVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (127.4%) | (47.7%) | 4% |
|
| ROE | (799.5%) | (55.0%) | 0% |
|
| Liabilities to Assets | 96.7% | 29.4% | 93% |
|
| F-Score | 3 | 2 | 18% |
|
Biohaven Ltd. did not pass any screens on 10/12/2026.
